BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 22646747)

  • 21. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
    Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
    Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.
    Ahmed AA; Zhang L; Reddivalla N; Hetherington M
    Pediatr Hematol Oncol; 2017 Apr; 34(3):165-185. PubMed ID: 28662353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma.
    Di Cataldo A; Dau D; Conte M; Parodi S; De Bernardi B; Giuliano M; Pession A; Viscardi E; Luksch R; Castellano A; Bertuna G; Haupt R;
    Med Sci Monit; 2009 Jan; 15(1):MT11-8. PubMed ID: 19114976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of biologic factors on the surgical decision in advanced neuroblastoma.
    Hsu WM; Jen YM; Lee H; Kuo ML; Tsao PN; Chen CN; Lai DM; Lin MT; Lai HS; Chen WJ; Hsieh FJ
    Ann Surg Oncol; 2006 Feb; 13(2):238-44. PubMed ID: 16418884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-directed therapy and research in neuroblastoma.
    Liu YL; Miser JS; Hsu WM
    J Formos Med Assoc; 2014 Dec; 113(12):887-9. PubMed ID: 25499951
    [No Abstract]   [Full Text] [Related]  

  • 27. Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma.
    Terui E; Matsunaga T; Yoshida H; Kouchi K; Kuroda H; Hishiki T; Saito T; Yamada S; Shirasawa H; Ohnuma N
    Clin Cancer Res; 2005 May; 11(9):3280-7. PubMed ID: 15867224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
    Gupta A; Williams BR; Hanash SM; Rawwas J
    Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic markers for neuroblastoma risk estimation: superseding tumor stage, age and MYCN?
    Oberthuer A
    Biomark Med; 2013 Dec; 7(6):905-8. PubMed ID: 24266822
    [No Abstract]   [Full Text] [Related]  

  • 30. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.
    Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP
    Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk estimation of neuroblastoma patients using molecular markers.
    Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
    Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
    Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use].
    Pérel Y; Valteau-Couanet D; Michon J; Lavrand F; Coze C; Bergeron C; Notz A; Plantaz D; Chastagner P; Bernard F; Thomas C; Rubie H
    Arch Pediatr; 2004 Jul; 11(7):834-42. PubMed ID: 15234382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroblastoma: biology, prognosis, and treatment.
    Park JR; Eggert A; Caron H
    Pediatr Clin North Am; 2008 Feb; 55(1):97-120, x. PubMed ID: 18242317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
    Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
    J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
    Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study.
    Sung KW; Son MH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ; Lee SK; Choi YS; Lim DH; Kim JS; Kim DW
    Bone Marrow Transplant; 2013 Jan; 48(1):68-73. PubMed ID: 22635247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.